leisure time -WSS

leisure time

author：focus 2025-09-14 14:46:20 - browse：8642

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Medicare wants to send $9 billion to 340B hospitals

WSS

Swim instructor mom warns parents not to buy blue swimsuits for kids

DOJ, FTC to increase scrutiny of all types of health care mergers

Biden declares emergency in flood

Norman Reedus' Daryl Dixon

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Celebrate National Dole Whip Day for 3 days this week at Disney

hotspot

leisure time

hotspot

Psychedelics group wrestles with new pharma identity

Biden targets hefty hospital 'facility fees' that often surprise patients

What does generative AI mean for health care? We asked experts

'Reaching a detente': STAT's Helen Branswell on covering Covid

DIEP, the 'gold standard' of breast reconstruction, is under threat

Seattle police shoot person suspected in downtown stabbing

In age of alternative facts, a scholarly course on calling out crap

Wisconsin governor employs partial veto to fund schools for 4 centuries

FDA approval of Sarepta Duchenne genetic therapy gives me hope

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

hotspot

The aspartame in Diet Coke probably isn’t giving you cancer

Researchers separate signal from noise in heart wearable data

ACA's risk program benefits Blue Cross Blue Shield insurers

'Reaching a detente': STAT's Helen Branswell on covering Covid

Medical experts are missing from AI regulatory conversations

DOJ, FTC to increase scrutiny of all types of health care mergers

hotspot

explore

leisure time

explore